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Protocol
AbstrAct
Introduction Over 18 000 children are admitted annually 
to UK paediatric intensive care units (PICUs), of whom 
nearly 75% receive respiratory support (invasive and/
or non-invasive). Continuous positive airway pressure 
(CPAP) has traditionally been used to provide first-line 
non-invasive respiratory support (NRS) in PICUs; however, 
high-flow nasal cannula therapy (HFNC), a novel mode of 
NRS, has recently gained popularity despite the lack of 
high-quality trial evidence to support its effectiveness. This 
feasibility study aims to inform the design and conduct of a 
future definitive randomised clinical trial (RCT) comparing 
the two modes of respiratory support.
Methods and analysis We will conduct a three-
centre randomised feasibility study over 12 months. 
Patients admitted to participating PICUs who satisfy 
eligibility criteria will be recruited to either group A 
(primary respiratory failure) or group B (postextubation). 
Consent will be obtained from parents/guardians prior 
to randomisation in ‘planned’ group B, and deferred in 
emergency situations (group A and ‘rescue’ group B). 
Participants will be randomised (1:1) to either CPAP or 
HFNC using sealed, opaque envelopes, from a computer-
generated randomisation sequence with variable block 
sizes. The study protocol specifies algorithms for the 
initiation, maintenance and weaning of HFNC and CPAP. 
The primary outcomes are related to feasibility, including 
the number of eligible patients in each group, feasibility 
of randomising >50% of eligible patients and measures 
of adherence to the treatment protocols. Data will also be 
collected on patient outcomes (eg, mortality and length 
of PICU stay) to inform the selection of an appropriate 
outcome measure in a future RCT. We aim to recruit 120 
patients to the study.
Ethics and dissemination Ethical approval was granted 
by the National Research Ethics Service Committee North 
East—Tyne&Wear South (15/NE/0296). Study findings will 
be disseminated through peer-reviewed journals, national 
and international conferences.
Trials registration number NCT02612415; pre-results.
Background
Each year, over 18 000 critically ill children 
are admitted to paediatric intensive care 
units (PICU) in the UK.1 Irrespective of the 
primary reason for admission, respiratory 
support is the most common intervention 
undertaken in PICU; national audit data 
from the Paediatric Intensive Care Audit 
Network demonstrate that nearly 75% of 
admissions between 2011 and 2013 received 
either invasive (via an endotracheal tube or 
tracheostomy) and/or non-invasive respira-
tory support during their PICU stay.1
Although invasive ventilation can be 
life saving, concerns regarding its complica-
tions, such as ventilator-induced lung injury, 
need for prolonged sedation and nosocomial 
respiratory tract infections have encour-
aged the greater adoption of non-invasive 
Strengths and limitations of this study
 ► This randomised trial aims to test the feasibility of 
comparing two modes of non-invasive respiratory 
support in critically ill children.
 ► If shown to be feasible, this study will inform the 
design and conduct of a future definitive randomised 
trial (RCT) comparing high-flow nasal cannula 
therapy with continuous positive airway pressure.
 ► In addition to testing feasibility, data will be 
collected on several secondary outcomes to inform 
the selection of an appropriate primary outcome 
measure for a future RCT.
 ► As a feasibility study run in three study sites, this 
study does not however have the power to show 
clinical effectiveness.
 ► This feasibility trial will not be assessing the cost 
effectiveness of the two treatments.
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respiratory support (NRS) techniques in intensive care 
settings.2–4 In critically ill adults and premature newborns, 
evidence from randomised clinical trials (RCT) supports 
the early use of NRS to reduce invasive ventilation and 
improve survival in specific patient subgroups.5–8 In 
critically ill infants and children, there is a dearth of high-
quality RCT evidence,9 yet, the use of NRS has increased 
over the years in UK PICUs as well as internationally.10
Continuous positive airway pressure (CPAP) has tradi-
tionally been used as the first-line mode of NRS in the 
PICU setting, to either avoid intubation and invasive 
ventilation or to avoid reintubation after extubation, 
following a spell of invasive ventilation.11 12 However, the 
widespread use of CPAP is limited by two main problems: 
(1) the need for a tight-fitting patient interface such 
as face mask, hood or nasal prongs to avoid leakage of 
gas from the ventilator circuit (which frequently causes 
patient discomfort/agitation as well as nasal and facial 
pressure sores with prolonged use, leading to treatment 
failure) and (2) the risk of serious complications such as 
pneumothorax or pneumomediastinum (which usually 
necessitates close monitoring and a high level of skilled 
nursing input).
Over the past decade, a novel mode of NRS, heat-
ed-humidified high-flow nasal cannula therapy (HFNC), 
has rapidly gained popularity despite the absence of 
RCT evidence to support its effectiveness in the PICU 
setting.13 14 The main reason for its increasing use is 
related to patient comfort and ease of use.15 HFNC does 
not require a tight seal and its patient interface (nasal 
prongs) is well tolerated by children. There is strong 
evidence from physiological and observational studies 
to support the use of HFNC in PICU—HFNC allows the 
delivery of heated and humidified medical gases to the 
patient at high-gas flow rates (matching or exceeding 
the patient’s own peak inspiratory flow rate), which 
has been shown to confer a diverse range of beneficial 
effects such as reduction of airway resistance, reduction 
of dead space by nasopharyngeal washout with fresh gas, 
as well as delivery of positive airway pressure (similar to 
CPAP).16 17 Studies in infants and children confirm that 
HFNC reduces the work of breathing and improves 
oxygenation and ventilation.18 19 In single-centre obser-
vational studies, the use of HFNC has been shown to be 
associated with a dramatic reduction in the rate of intuba-
tion and invasive ventilation.20–22 However, there have not 
yet been any RCTs comparing HFNC with other forms of 
NRS such as CPAP in the PICU setting.23
Before an expensive health technology such as HFNC is 
adopted more widely across the paediatric intensive care 
setting, it is crucial that evidence from a large pragmatic 
RCT is urgently available to support its clinical and cost 
effectiveness, especially since loss of clinical equipoise 
regarding the risks and benefits of HFNC is already occur-
ring among clinicians.24 Prior to a national RCT, however, 
it is imperative that the feasibility of conducting such an 
RCT is established. In this paper, we describe the protocol 
for a multicentre randomised feasibility trial to compare 
the two most commonly used modes of NRS (CPAP and 
HFNC) in critically ill children admitted to PICU (V.2.1, 
17 March 2016).
STudy aim
The aim of this study is to conduct a feasibility study to 
inform the design and conduct of a future definitive 
multicentre RCT comparing two commonly used modes 
of non-invasive respiratory support (CPAP and HFNC) in 
the PICU setting.
STudy oBjecTiveS
Primary objective: To determine the feasibility of an RCT 
of HFNC versus CPAP in critically ill children admitted 
to PICU.
Secondary objectives:
 ► to determine the rate of intubation and invasive 
ventilation (or reintubation) in each study arm
 ► to determine the rate of treatment failure in each 
study arm
 ► to assess the safety of the use of CPAP and HFNC
 ► to assess the physiological effects of CPAP and HFNC
 ► to assess the effect of CPAP and HFNC on patient 
outcomes.
STudy deSign and SeTTing
This is a randomised, controlled, open-label clinical trial 
comparing HFNC with CPAP as the first-line non-inva-
sive respiratory support modality in critically ill children. 
Patients will be recruited at three PICUs in London. 
Together, these PICUs admit around 2500 children annu-
ally. The frequency of NRS use is variable on the units 
(between 15% and 43% of admissions) owing to differ-
ences in availability of beds for high-dependency care. All 
three units have access to both modes of NRS (CPAP and 
HFNC).
incluSion criTeria
Pragmatic inclusion criteria will be used. To minimise vari-
ation in practice between and within centres, predefined, 
objective criteria are provided to clinicians to guide the 
decision on when to start NRS. Eligible patients aged 
between >36 weeks corrected gestational age and <16 
years will fall into one of two groups:
Group A (step-up)
 ► Deemed by the treating clinician to require NRS for 
an acute illness;
 ► Satisfy one or more of the following criteria:
 ► hypoxia (oxygen saturation <92% in fraction of 
inspired oxygen >0.40, or equivalent)
 ► acute respiratory acidosis (pH <7.3 with a 
concomitant partial pressure of carbon dioxide 
>6.5 kPa)
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 ► moderate respiratory distress (use of accessory 
muscles, subcostal and intercostal recession, 
tachypnoea for age, grunting).
Group B (step-down)
Deemed by the treating clinician to require NRS 
following a spell of invasive ventilation, either immedi-
ately after extubation as a planned procedure (‘planned’) 
or prompted by clinical deterioration within 72 hours 
after extubation (‘rescue’).
‘Rescue’ participants will be required to also satisfy one 
or more of the following criteria: hypoxia, acute respira-
tory acidosis or moderate respiratory distress (using the 
same definitions as above).
excluSion criTeria
Patients will be excluded if they (1) are deemed by the 
treating clinician to require immediate intubation/inva-
sive ventilation due to severe hypoxia, acidosis and/or 
respiratory distress, upper airway obstruction or recur-
rent apnoeas; (2) have a tracheostomy in place; (3) have 
a pre-existing air-leak syndrome (pneumothorax and/or 
pneumomediastinum); (4) have midfacial/craniofacial 
anomalies (unrepaired cleft palate, choanal atresia) or had 
recent craniofacial surgery; (5) have an agreed limitation 
of intensive care treatment plan in place (‘not for intuba-
tion’); (6) have been on domiciliary NRS prior to PICU 
admission; (7) have been managed on either HFNC and/
or CPAP (or other form of NRS such as bilevel positive 
airway pressure (BiPAP)) in the preceding 24 hours; (8) 
have been previously recruited to the study during the same 
PICU admission; (9) cannot be treated with HFNC due to 
unavailability of appropriate sized nasal prongs or HFNC 
device; or (10) cannot be treated with CPAP due to unavail-
ability of right size of face mask, prong or other patient 
interface or CPAP device.
Screening for eligiBiliTy
A Consolidated Standards for Reporting Trials (CONSORT) 
flow diagram is shown in figure 1. Clinical and/or the 
research nurse teams will assess patients admitted to study 
PICUs to identify potentially eligible study participants. 
Screening procedures will be different for Groups A and B. 
For Group B, all invasively ventilated patients on the PICU 
will be screened daily to identify children who are planned 
Figure 1 Planned flow of patients through the FIRST-line support for Assistance in Breathing in Children feasibility trial.
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for extubation. The treating clinician will be approached 
to establish whether the patient would be placed on NRS 
immediately after extubation irrespective of clinical condi-
tion (‘planned’), or whether NRS would only be used as 
a ‘rescue’ treatment after extubation. A screening log of 
all patients who fulfil inclusion criteria but meet exclusion 
criteria, as well as a log of eligible patients who are not 
recruited to the study, will be maintained.
PaTienT recruiTmenT and conSenT
A mixed model of consent will be utilised (prospective 
and deferred) appropriate to the nature of the clinical 
situation (planned initiation of NRS or emergency initi-
ation of NRS). Informed consent will be supported by 
providing information to parents/guardians at different 
stages of the patient pathway.
Group A: Patients requiring NRS as a ‘step-up’ treat-
ment will most often need this started in a life-threatening 
emergency, where any delay in commencing treatment 
will be detrimental, making any attempt to obtain fully 
informed consent from parents/guardians during an 
emergency inappropriate and cause additional stress to 
families who are already distressed by their child’s illness. 
Therefore, consent in this situation will be deferred. 
Figure 2 Study algorithm for the management of patients randomised to HFNC. BiPAP, bi-level positive airway pressure; 
CPAP, continuous positive airway pressure; FiO2, fraction of inspired oxygen; HFNC, high-flow nasal cannula; PaO2, partial 
pressure of arterial oxygen; pCO2, partial pressure of carbon dioxide.
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Once notified of the recruitment of a patient to the 
study, the clinical/research nurse team will approach 
the parents/guardians as soon as practically possible 
after randomisation (usually within 24–48 hours) to 
discuss the study, provide written information and seek 
informed consent. Consent will be sought for continu-
ation in the trial and for data collection from routine 
medical records. Both modes of NRS (CPAP and HFNC) 
are relatively safe, commonly used in clinical practice 
and in practice only determined by individual clinician 
preferences.
Group B: Patients requiring NRS as a ‘step-down’ 
treatment will be receiving invasive ventilation on 
PICU. Therefore, there will be sufficient time during 
which the clinical/research nurse team can discuss 
the study and provide detailed written information to 
the parents/guardians. Following this discussion, if 
parents/guardians refuse to participate in the research, 
no further involvement in the study will be consid-
ered. If NRS is ‘planned’ following extubation by the 
treating clinician, written consent will be obtained from 
parents/guardians by the clinical/research nurse team 
before randomisation. If NRS is initiated as a ‘rescue’ 
intervention following extubation, written consent may 
be deferred, depending on parental availability and the 
emergency nature of the situation. This was left at the 
discretion of the clinical team.
Due to the use of deferred consent, there may be rare 
situations where the patient is either: (1) discharged 
from hospital prior to consent being obtained from 
the parents/guardians or (2) the patient dies prior 
to consent being sought. In the former situation, we 
will aim to obtain postal consent as soon as possible 
after discharge, by sending parents/guardians study 
Figure 3 Study algorithm for the management of patients randomised to CPAP. BiPAP, bi-level positive airway pressure; CPAP, 
continuous positive airway pressure; FiO2, fraction of inspired oxygen; HFNC, high-flow nasal cannula; pCO2, partial pressure of 
carbon dioxide; SpO2, normal blood oxygen saturation level.
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information on two separate occasions 4 weeks apart. If 
no consent form is received within 4 weeks of receipt of 
the letter, then the participants’ data will be included in 
the study unless the family notify the site research team 
otherwise. In the latter situation, the parents/guard-
ians will not be informed of their child’s involvement 
in the trial as this may cause unnecessary and avoid-
able distress. Data up to the patient’s death will still be 
collected and used as part of the study, as there may be 
a risk of bias if this was removed.
If prior consent is not provided for patients in group B, 
they will not be randomised to the trial. A minimal dataset 
will be collected for each patient approached but not 
randomised including study site, date/time approached 
and reason for non-consent. If deferred consent is not 
provided for patients in group A following randomisa-
tion, no further data will be collected from the child 
and the child will be recorded as not consented. Data 
collected up to the point of parental refusal of consent 
will be used. A minimal dataset will be collected for each 
patient randomised but not consented including study 
site, date/time randomised, randomised intervention 
(including whether started on assigned intervention or 
not) and reason for non-consent.
randomiSaTion and Blinding
Randomisation will be performed as soon as possible 
after identifying the child as being eligible for the 
study (no later than 24 hours). Prerandomisation strat-
ification will be by group (A or B) and by study site. 
Eligible patients will be randomised on a 1:1 basis to 
either CPAP or HFNC using sealed, opaque envelopes 
available at each centre. The randomisation sequence 
will be computer generated with variable block sizes to 
strengthen allocation concealment. The intervention 
in this study cannot be blinded, since both treatments 
(CPAP and HFNC) are already used in practice and 
recognisable by clinical staff. Study investigators, 
including those performing the final analysis, will be 
blinded to the allocation.
STudy inTervenTion
A commercially available and Conformité 
Européene (CE)-marked HFNC device will be used to 
deliver a prescribed gas flow rate for the duration that the 
patient needs NRS. The study protocol specifies clinical 
criteria and procedures for the initiation, maintenance 
and weaning of HFNC (see figure 2 for study algorithm). 
As per current practice, clinicians in the study will be 
able to stop HFNC and crossover to CPAP if clinically 
deemed necessary. Prespecified objective criteria will be 
provided in the study protocol as a guide for clinicians 
considering crossover from HFNC to CPAP to identify 
non-responders to HFNC. Reasons for crossover will be 
recorded. Crossover patients will remain in the study and 
continue to be monitored until they are off respiratory 
support.
conTrol
A commercially available and CE-marked CPAP device 
will be used to provide a set expiratory pressure of 6–8 cm 
H2O for the duration that the infant needs NRS. The 
study protocol specifies clinical criteria and procedures 
for the initiation, maintenance and weaning of CPAP 
(see figure 3 for study algorithm). As per current prac-
tice, clinicians will be able to stop CPAP and crossover 
to HFNC only if the patient has significant discomfort/
intolerance to the CPAP. Crossover patients will remain 
in the study and continue to be monitored until they are 
off respiratory support.
Table 1 Schedule of events
PICU admission 
OR
prior to extubation Study entry
Hourly for first
6 hours
At 12, 24, 36, 48 
and 72 hours until 
end of treatment
Hospital 
discharge
(or death) At day 28
Screening for eligibility x
Informed consent and 
consent questionnaire
x x*
Randomisation x
Treatment (HFNC or 
CPAP)
x x
Physiology x x
COMFORT score x x
PSS:PICU Questionnaire
(at 24 hours only)
x
Hospital stay data x
Safety monitoring x
*Deferred consent will be sought as soon as practically possible, usually within 48 hours.
CPAP, continuous positive airway pressure; HFNC, high-flow nasal cannula; PSS, Parental Stressor Scale; PICU, Paediatric Intensive Care 
Unit.
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clinical managemenT
Recruited patients will be treated as per the study protocol 
with respect to the provision of NRS. Due to the pragmatic 
nature of the trial, all other treatment in both groups will 
be as per standard practice at the study sites. Infants who 
fail to improve on CPAP or HFNC may be escalated to 
other non-invasive modes of ventilation such as BiPAP or 
pressure support (before intubation and ventilation) as 
per the treating clinician’s discretion.
daTa collecTion
A full schedule of assessments is provided in table 1. 
Patient demographics will be collected at randomisation 
(age, gender, primary reason for PICU admission, comor-
bidities). Routine clinical observations such as normal 
blood oxygen saturation level, fraction of inspired oxygen, 
potential of hydrogen, partial pressure of carbon dioxide, 
heart rate, respiratory rate and clinical signs of respiratory 
distress, a modified COMFORT score to indicate patient 
tolerance to the treatment (excluding the respiratory 
component) and use of sedative agents to improve toler-
ance to the treatment will be collected at the start of the 
randomised treatment and assessed on an hourly basis for 
the first 6 hours, then at 12, 24, 36, 48 and 72 hours until 
the end of the assigned treatment (or crossover, escala-
tion or intubation/ventilation). A consent questionnaire 
used in other paediatric RCTs using deferred consent 
(CATCH trial, ISRCTN34884569 and EcLiPSE trial, 
ISRCTN22567894) will be administered to all parents/
guardians (see online supplementary material 1) irre-
spective of whether consent is provided to participate in 
the trial or not.25–27 Parents/guardians will also be asked 
to complete a validated instrument, the Parental Stressor 
Scale: Paediatric Intensive Care Unit (PSS:PICU) ques-
tionnaire, around 24 hours after initiation of NRS to assess 
parental stress (see online supplementary material 2).28 
Adverse events will be collected and assessed for duration, 
causality, expectedness, seriousness and severity.
daTa managemenT and moniToring
Study data, including serious adverse events, will be 
collected and managed using Research Electronic Data 
Capture (REDCap) electronic data capture tools managed 
by the Intensive Care National Audit and Research 
Centre (ICNARC) Clinical Trials Unit (CTU).29 REDCap 
is a secure, web-based application designed to support 
data capture for research studies, providing (1) an intui-
tive interface for validated data entry, (2) audit trails for 
tracking data manipulation and export procedures, (3) 
automated export procedures for seamless data down-
loads to common statistical packages and (4) procedures 
for importing data from external sources. Study partici-
pants will be identified by a unique study specific number. 
The name and any other identifying detail will not be 
included in any study data electronic file. Research assis-
tants and statisticians will carry out periodic data quality 
checks and clarify data errors with research sites.
This is a low-risk trial and major safety data are not antic-
ipated. Serious adverse events (SAEs) will be reported 
to the ICNARC CTU unless otherwise defined in the 
protocol. Trends in SAEs will be monitored by the CTU, 
and unexpected SAEs will be notified to the Sponsor. 
The ICNARC CTU will conduct at least one monitoring 
visit to participating sites during the course of the trial. 
No formal data monitoring and ethics committee will be 
established since this is a feasibility study.
ouTcome meaSureS
The primary outcomes are related to the primary study 
objective, namely determining the feasibility of a future 
RCT: (1) number of eligible patients in group A (step-up 
treatment) and group B (step-down treatment); (2) feasi-
bility of randomising at least 50% of eligible patients; (3) 
acceptability of using a mixed model of consent (prospec-
tive and deferred); (4) adherence to the study protocol 
in terms of initiation, maintenance and weaning of the 
study treatments; (5) use of a modified COMFORT score 
to assess patient tolerance; and (6) use of the PSS:PICU 
questionnaire to measure parental stress 24 hours after 
the initiation of the treatment. Data will be collected 
on patient outcomes to inform the choice of an appro-
priate outcome measure for the definitive trial (rate of 
intubation, rate of treatment failure, rate of crossover/
escalation, length of stay on PICU and in hospital, length 
of invasive and non-invasive ventilation and mortality in 
PICU and at hospital discharge).
daTa analySiS
We will use intention-to-treat analysis to perform any 
comparisons between the groups, although as a feasibility 
study, this is not the main aim of the trial. Since crossover 
will be allowed, we will also perform a per-protocol anal-
ysis. We will calculate the rate of recruitment (number 
of patients randomised/number of eligible patients) 
for each group, the consent rate (number of patients 
consented/number of patients approached for consent) 
for prospective and deferred consent, rate of crossover 
(number of patients crossed over to the other treatment/
number of patients randomised to the treatment) for 
each arm, the rate of intubation (number of patients 
needing intubation/number of patients randomised to 
the treatment) for each arm and the frequency of serious 
adverse events occurring in each treatment arm. As a feasi-
bility study, no formal sample size calculations have been 
performed. Based on analysis of audit data, we expect 
around 250 eligible patients over the 6-month period at 
the three sites. Assuming a 50% recruitment rate, we will 
have recruited 120 study patients (around 40 patients in 
group A). Data from the literature suggests a 20% rate of 
intubation for group A (ie, we expect to see eight intuba-
tion events) and a 10% rate of reintubation for group B 
(ie, we expect to see eight reintubation events).
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eThical aPProval and regulaTory conSideraTionS
Ethical approval was provided by the National Research 
Ethics Service Committee North East—Tyne and Wear 
South (ref: 15/NE/0296). Approval was obtained from 
all participating sites’ research and development depart-
ments prior to the study initiation. The study protocol, 
patient information sheets, informed consent forms 
and other study-related documents were reviewed and 
approved by the Sponsor and Research Ethics Committee 
with respect to scientific content and compliance 
with applicable research regulations involving human 
subjects. Since the trial involves the use of CE-marked 
medical devices employed for their intended purpose, it 
is not considered to be a clinical investigation under the 
Medical Devices Regulations 2002, nor does it fall within 
the remit of the Medicines for Human Use (Clinical 
Trials) Regulations 2004. The study will comply with the 
Data Protection Act, 1998.
diSSeminaTion STraTegy
The results of the study will be reported and disseminated 
via peer-reviewed scientific journals, conference presen-
tations and written feedback to patient support groups.
diScuSSion
Although CPAP has been used as a mode of non-invasive 
respiratory support for over two decades, its use in criti-
cally ill children is not supported by clinical trial evidence.9 
HFNC therapy has recently become a popular alternative 
to CPAP since it is better tolerated by patients and is easy 
to use.30 31 Although observational studies indicate that 
the use of HFNC may reduce the need for intubation/
invasive ventilation, there have been no RCTs comparing 
the clinical and cost-effectiveness of HFNC with CPAP in 
critically ill children.20–22 32
The design and conduct of a definitive RCT comparing 
HFNC and CPAP in critically ill children potentially 
involves several challenges. First, since the use of HFNC 
has superseded the use of CPAP in many paediatric 
settings, there is a risk that some clinicians (and/or 
parents) may be reluctant to randomise patients to one or 
the other treatment. Second, the lack of robust evidence 
to guide clinicians on when and which patients to select 
for NRS has resulted in variability in clinical practice; this 
makes it important that any study algorithms used for the 
initiation, maintenance and weaning of HFNC/CPAP are 
acceptable to clinicians and practical to use. Third, since 
RCTs involving the use of HFNC in premature newborns 
and adults have studied a range of clinical outcomes with 
varying results,33–36 an important consideration for PICU 
patients is the choice of an appropriate and clinically rele-
vant outcome measure. For all these reasons, it is crucial 
that a future definitive RCT is preceded by a feasibility 
trial. Findings from the FIRST-line support for Assistance 
in Breathing in Children feasibility trial will be used to 
inform the design and conduct of a future definitive trial.
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